Biotechnology - Hematology

Filter

Current filters:

Hematology

Popular Filters

1 to 25 of 33 results

Spark Thera in potential $280 million hemophilia B deal with Pfizer

Spark Thera in potential $280 million hemophilia B deal with Pfizer

10-12-2014

US gene therapy start up Spark Therapeutics has entered into a global collaboration with pharma giant…

BiotechnologyHematologyLicensingPfizerSpark TherapeuticsSPK-RPE65USA

Onxeo receives $25M milestone payment from Spectrum on Beleodaq

14-11-2014

Onxeo, created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company…

BeleodaqBiotechnologyFinancialHematologyLicensingOncologyOnxeoSpectrum PharmaceuticalsUSA

Geron in up to $935 million deal with Janssen for imetelstat

Geron in up to $935 million deal with Janssen for imetelstat

14-11-2014

Geron Corp has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech,…

BiotechnologyGeron CorpGlobalHematologyimetelstatJanssen BiotechJohnson & JohnsonLicensingOncology

Biogen Idec and SOBI’s Elocta MAA validated in Europe

01-11-2014

Biotechnology companies Biogen Idec of the USA and Swedish Orphan Biovitrum said on Friday that the European…

Biogen IdecBiotechnologyEloctaEloctateEuropeHematologyRegulationSwedish Orphan Biovitrum

Octapharma mulls building hemophilia product plant in Russia

27-10-2014

Independent Swiss biotech company Octapharma is considering building a plant for production of drugs…

BiotechnologyHematologyOctapharmaProductionRussia

SOBI and Pharming extend and amend Ruconest agreement

SOBI and Pharming extend and amend Ruconest agreement

13-10-2014

Biotech companies Pharming Group and Swedish Orphan Biovitrum have amended and extended the Ruconest…

BiotechnologyHematologyMarkets & MarketingPharmingRuconestSobiSweden

Biogen Idec files for Elocta approval in Europe

Biogen Idec files for Elocta approval in Europe

10-10-2014

US biotech firm Biogen Idec has submitted a Marketing Authorization Application (MAA) for Elocta (rFVIIIFc;…

Biogen IdecBiotechnologyEloctaEloctateEuropeHematologyRegulationSwedish Orphan Biovitrum

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

19-09-2014

Nordic biotech firm Swedish Orphan Biovitrum has added the preclinical fusion molecule rFVIIIFc-XTEN-vWF…

Biogen IdecBiotechnologyHematologyLicensingSobiSweden

NICE draft guidance recommends Alexion’s Soliris for very rare life-threatening blood disorder

NICE draft guidance recommends Alexion’s Soliris for very rare life-threatening blood disorder

04-09-2014

A drug to treat a very rare blood disorder affecting around 200 people in England has been recommended…

Alexion PharmaceuticalsBiotechnologyHematologyPricingRare diseasesRegulationSolirisUK

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

26-08-2014

Canadian regulator Health Canada has approved US Biotech major Biogen Idec’s Eloctate (antihemophilic…

Biogen IdecBiotechnologyCanadaEloctateHematologyRegulationSwedish Orphan Biovitrum

Novartis makes investment in stem cell company Gamida Cell with option agreement

Novartis makes investment in stem cell company Gamida Cell with option agreement

19-08-2014

Swiss drug major Novartis has signed an investment and option agreement with Israeli stem cell specialist…

BiotechnologyFinancialGamida CellHematologyIsraelNovartisStem cell specialistSwitzerland

Baxter opens its first state-of-the-art biologics facility in Asia

Baxter opens its first state-of-the-art biologics facility in Asia

08-08-2014

US drugmaker Baxter International has formally opened its S$370 million ($297 million) first advanced…

AdvateBaxter InternationalBiotechnologyEuropean Medicines AgencyHematologyHemophilia BProductionSingapore

EU approval for Octapharma's Nuwiq across all age groups in hemophilia A

EU approval for Octapharma's Nuwiq across all age groups in hemophilia A

07-08-2014

The European Commission has approved independent Swiss biotech firm Octapharma's Nuwiq (simoctocog alfa)…

BiotechnologyEuropeHematologyNuwiqOctapharmaRegulation

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

Bayer strikes deal with Dimension Therapeutics to develop hemophilia A gene therapy

23-06-2014

USA-based venture capital;-backed biotech Dimension Therapeutics has entered into a collaboration with…

BayerBiotechnologyDimension TheapeuticsHematologyLicensingResearch

Geron leaps as FDA lifts partial hold on imetelstat trial

Geron leaps as FDA lifts partial hold on imetelstat trial

13-06-2014

US biotech Geron Corp's shares jumped around 27% to $3.31 in early afternoon trading yesterday after…

BiotechnologyGeron CorpHematologyimetelstatOncologyRegulationUSA

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

10-06-2014

Dutch/Belgian preclinical stage biotech company arGEN-X, has entered into a partnership with The Leukemia…

arGEN-XARGX-110BiotechnologyHematologyOncologyResearch

Biogen Idec’s Eloctate gains FDA approval

Biogen Idec’s Eloctate gains FDA approval

09-06-2014

The US Food and Drug Administration on Friday approved US biotech firm Biogen Idec’s Eloctate, antihemophilic…

Biogen IdecBiotechnologyEloctateHematologyRegulationSwedish Orphan BiovitrumUSA

CSL opens Australian biotechnology manufacturing facility

09-05-2014

Leading Australian biotech firm CSL Limited has opened the CSL Behring Biotechnology manufacturing facility…

AustraliaBiotechnologyCSL BehringCSL LimitedHematologyProductionResearch

Biogen Idec exercises option for Amunix’ XTENylated Factor VIII

21-04-2014

US privately-held biotech firm Amunix Operating says that Biogen Idec has exercised its option to enter…

AmunixBiogen IdecBiotechnologyHematologyLicensing

Baxter to acquire Chatham Therapeutics for $70 million

03-04-2014

USA-based Baxter International says it has agreed to acquire Chatham Therapeutics, a private biotechnology…

Baxter InternationalBiotechnologyChatham TherapeuticsHematologyMergers & Acquisitions

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

20-03-2014

US biotech company Emmaus Life Sciences, which focuses on orphan diseases, has announced preliminary…

BiotechnologyHematologyResearchUSA

1 to 25 of 33 results

Back to top